Literature DB >> 11420480

Skeletonizing en bloc esophagectomy for cancer.

J M Collard1, J B Otte, R Fiasse, P F Laterre, M De Kock, J Longueville, D Glineur, R Romagnoli, M Reynaert, P J Kestens.   

Abstract

OBJECTIVE: To evaluate the long-term outcome of patients with esophageal cancer after resection of the extraesophageal component of the neoplastic process en bloc with the esophageal tube. SUMMARY BACKGROUND DATA: Opinions are conflicting about the addition of extended resection of locoregional lymph nodes and soft tissue to removal of the esophageal tube.
METHODS: Esophagectomy performed en bloc with locoregional lymph nodes and resulting in a real skeletonization of the nonresectable anatomical structures adjacent to the esophagus was attempted in 324 patients. The esophagus was removed using a right thoracic (n = 208), transdiaphragmatic (n = 39), or left thoracic (n = 77) approach. Lymphadenectomy was performed in the upper abdomen and lower mediastinum in all patients. It was extended over the upper mediastinum when a right thoracic approach was used and up to the neck in 17 patients. Esophagectomy was carried out flush with the esophageal wall as soon as it became obvious that a macroscopically complete resection was not feasible. Neoplastic processes were classified according to completeness of the resection, depth of wall penetration, and lymph node involvement.
RESULTS: Skeletonizing en bloc esophagectomy was feasible in 235 of the 324 patients (73%). The 5-year survival rate, including in-hospital deaths (5%), was 35% (324 patients); it was 64% in the 117 patients with an intramural neoplastic process versus 19% in the 207 patients having neoplastic tissue outside the esophageal wall or surgical margins (P <.0001). The latter 19% represented 12% of the whole series. The 5-year survival rate after skeletonizing en bloc esophagectomy was 49% (235 patients), 49% for squamous cell versus 47% for glandular carcinomas (P =.4599), 64% for patients with an intramural tumor versus 34% for those with extraesophageal neoplastic tissue (P <.0001), and 43% for patients with fewer than five metastatic nodes versus 11% for those with involvement of five or more lymph nodes (P =.0001).
CONCLUSIONS: The strategy of attempting skeletonizing en bloc esophagectomy in all patients offers long-term survival to one third of the patients with resectable extraesophageal neoplastic tissues. These patients represent 12% of the patients with esophageal cancer suitable for esophagectomy and 19% of those having neoplastic tissue outside the esophageal wall or surgical margins.

Entities:  

Mesh:

Year:  2001        PMID: 11420480      PMCID: PMC1421944          DOI: 10.1097/00000658-200107000-00005

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  30 in total

1.  Esophageal replacement: gastric tube or whole stomach?

Authors:  J M Collard; N Tinton; J Malaise; R Romagnoli; J B Otte; P J Kestens
Journal:  Ann Thorac Surg       Date:  1995-08       Impact factor: 4.330

2.  Improvement in staging of esophageal cancer with the addition of positron emission tomography.

Authors:  M I Block; G A Patterson; R S Sundaresan; M S Bailey; F L Flanagan; F Dehdashti; B A Siegel; J D Cooper
Journal:  Ann Thorac Surg       Date:  1997-09       Impact factor: 4.330

3.  Stage II esophageal carcinoma: the significance of T and N.

Authors:  W A Killinger; T W Rice; D J Adelstein; S V Medendorp; G Zuccaro; T J Kirby; J R Goldblum
Journal:  J Thorac Cardiovasc Surg       Date:  1996-05       Impact factor: 5.209

4.  Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus.

Authors:  J F Bosset; M Gignoux; J P Triboulet; E Tiret; G Mantion; D Elias; P Lozach; J C Ollier; J J Pavy; M Mercier; T Sahmoud
Journal:  N Engl J Med       Date:  1997-07-17       Impact factor: 91.245

5.  The pathologist and the residual tumor (R) classification.

Authors:  P Hermanek; C Wittekind
Journal:  Pathol Res Pract       Date:  1994-02       Impact factor: 3.250

6.  Transhiatal esophagectomy for carcinoma of the esophagus.

Authors:  W T Vigneswaran; V F Trastek; P C Pairolero; C Deschamps; R C Daly; M S Allen
Journal:  Ann Thorac Surg       Date:  1993-10       Impact factor: 4.330

7.  Radical lymph node dissection for cancer of the thoracic esophagus.

Authors:  H Akiyama; M Tsurumaru; H Udagawa; Y Kajiyama
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

8.  Nodal metastasis and sites of recurrence after en bloc esophagectomy for adenocarcinoma.

Authors:  G W Clark; J H Peters; A P Ireland; A Ehsan; J A Hagen; M T Kiyabu; C G Bremner; T R DeMeester
Journal:  Ann Thorac Surg       Date:  1994-09       Impact factor: 4.330

9.  En bloc and standard esophagectomies by thoracoscopy.

Authors:  J M Collard; B Lengele; J B Otte; P J Kestens
Journal:  Ann Thorac Surg       Date:  1993-09       Impact factor: 4.330

10.  Prognostic factors of resected adenocarcinoma of the esophagus.

Authors:  A H Hölscher; E Bollschweiler; R Bumm; H Bartels; H Höfler; J R Siewert
Journal:  Surgery       Date:  1995-11       Impact factor: 3.982

View more
  20 in total

1.  Laparoscopically assisted transhiatal resection for malignancies of the distal esophagus.

Authors:  W T Van den Broek; O Makay; F J Berends; J Z Yuan; A P J Houdijk; S Meijer; M A Cuesta
Journal:  Surg Endosc       Date:  2004-04-06       Impact factor: 4.584

Review 2.  Current management of esophageal cancer.

Authors:  Simon Law; John Wong
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

Review 3.  Surgical treatment of superficial esophageal cancer.

Authors:  Mitsuo Tachibana; Shoichi Kinugasa; Muneaki Shibakita; Yasuhito Tonomoto; Shinji Hattori; Ryoji Hyakudomi; Hiroshi Yoshimura; Dipok Kumar Dhar; Naofumi Nagasue
Journal:  Langenbecks Arch Surg       Date:  2006-07-08       Impact factor: 3.445

4.  Treatment of esophageal cancer: does surgery make the cut?

Authors:  Jack A Roth
Journal:  Gastrointest Cancer Res       Date:  2007-09

5.  Downregulation of MACC1 inhibits the viability, invasion and migration and induces apoptosis in esophageal carcinoma cells through the phosphatase and tensin homolog/phosphoinositide 3-kinase/protein kinase B signaling pathway.

Authors:  Li-Qiang Qian; Xia-Qin Li; Peng-Hui Ye; Hao-Yuan Su; Gang Wang; Yan Liu; Gen-Hai Shen; Quan-Gen Gao
Journal:  Oncol Lett       Date:  2017-08-23       Impact factor: 2.967

6.  Ivor Lewis subtotal esophagectomy with two-field lymphadenectomy for squamous cell carcinoma of the lower thoracic esophagus.

Authors:  Jie Wu; Ying Chai; Xing-Ming Zhou; Qi-Xun Chen; Fu-Lai Yan
Journal:  World J Gastroenterol       Date:  2008-08-28       Impact factor: 5.742

7.  DRD2/DARPP-32 expression correlates with lymph node metastasis and tumor progression in patients with esophageal squamous cell carcinoma.

Authors:  Li Li; Masaki Miyamoto; Yuma Ebihara; Seiji Mega; Ryo Takahashi; Ryunosuke Hase; Hiroyuki Kaneko; Masatoshi Kadoya; Tomoo Itoh; Toshiaki Shichinohe; Satoshi Hirano; Satoshi Kondo
Journal:  World J Surg       Date:  2006-09       Impact factor: 3.352

8.  Association of PYGO2 and EGFR in esophageal squamous cell carcinoma.

Authors:  Meysam Moghbeli; Mohammad Reza Abbaszadegan; Moein Farshchian; Mehdi Montazer; Reza Raeisossadati; Abbas Abdollahi; Mohammad Mahdi Forghanifard
Journal:  Med Oncol       Date:  2013-03-03       Impact factor: 3.064

9.  The first series of completely robotic esophagectomies with three-field lymphadenectomy: initial experience.

Authors:  K H Kernstine; D T DeArmond; D M Shamoun; J H Campos
Journal:  Surg Endosc       Date:  2007-06-26       Impact factor: 4.584

10.  Thoracoscopic resection for esophageal cancer: A review of literature.

Authors:  Joris J G Scheepers; Donald L van der Peet; Alexander A F A Veenhof; Miguel A Cuesta
Journal:  J Minim Access Surg       Date:  2007-10       Impact factor: 1.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.